Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash & Equivalents (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Cash & Equivalents for 9 consecutive years, with $29.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 57.19% year-over-year to $29.6 million, compared with a TTM value of $29.6 million through Dec 2025, down 57.19%, and an annual FY2025 reading of $29.6 million, down 57.19% over the prior year.
  • Cash & Equivalents was $29.6 million for Q4 2025 at Puma Biotechnology, down from $53.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $95.7 million in Q1 2021 and bottomed at $29.6 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $67.6 million, with a median of $65.5 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents rose 25.01% in 2024, then tumbled 57.19% in 2025.
  • Year by year, Cash & Equivalents stood at $63.1 million in 2021, then grew by 20.7% to $76.2 million in 2022, then increased by 11.0% to $84.6 million in 2023, then decreased by 18.17% to $69.2 million in 2024, then crashed by 57.19% to $29.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for PBYI at $29.6 million in Q4 2025, $53.5 million in Q3 2025, and $54.7 million in Q2 2025.